Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hutchmed
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Stanford University
INSYS Therapeutics Inc